Skip to main content
    I

    Insight Molecular Diagnostics Inc. (IMDX)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $1.86
    -0.28 (-13.08%)

    Market Cap: $70.03M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Insight Molecular Diagnostics Inc. (IMDX) Financials: Revenue, Profit and Cash Flow

    Updated Aug 10, 2026. Financial statements from company filings, amounts in US dollars.

    Insight Molecular Diagnostics reported revenue of $4.05M for the fiscal year ended Dec 31, 2025, up 115.6% from the year before. That year, net income was -$50.22M with a net margin of -1238.5%, operating cash flow was -$22.18M and free cash flow was -$25.37M. The quarter ended Jun 30, 2026 had revenue of $239.00K and net income of -$11.26M.

    Revenue and Margins

    Over the 5 years to Dec 2025, revenue grew from $1.22M, a compound annual rate of 27.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$4.05M+115.6%56.7%-1260.8%-1238.5%
    Dec 2024$1.88M+25.1%39.3%-3245.1%-3225.0%
    Dec 2023$1.50M+56.9%27.5%-1672.4%-1848.4%
    Dec 2022$958.00K-56.4%-1.9%-1878.6%-7609.8%
    Dec 2021$2.20M+80.8%64.6%-2444.3%-2916.2%
    Dec 2020$1.22MN/A-52.5%-2443.3%-2461.5%
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$4.05M$1.88M$1.50M$958.00K$2.20M$1.22M$0$0$0$0
    Cost of revenue$1.76M$1.14M$1.09M$976.00K$697.00K$1.85M$0$0$0$0
    Gross profit$2.30M$740.00K$413.00K-$18.00K$1.42M-$639.00K$0$0$0$0
    Research and development$15.90M$9.84M$9.29M$7.30M$5.04M$9.80M$6.79M$6.51M$7.17M$5.68M
    Operating income-$51.12M-$61.04M-$25.14M-$18.00M-$53.73M-$29.71M-$22.24M-$15.20M-$18.85M-$11.14M
    Net income-$50.22M-$60.66M-$27.78M-$72.90M-$64.10M-$29.93M-$22.43M-$15.75M-$19.38M-$11.17M
    EBITDA-$47.92M-$59.02M-$23.12M-$13.30M-$49.46M-$28.89M-$21.84M-$14.88M-$18.50M-$10.75M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$239.00K$32.00K$1.14M$260.00K$518.00K$2.14M$1.49M$115.00K$104.00K$176.00K$314.00K$429.00K
    Gross profit$157.00K$15.00K$484.00K$139.00K$338.00K$1.32M$595.00K$50.00K$50.00K$45.00K-$117.00K$248.00K
    Operating income-$11.40M-$4.41M-$23.43M-$11.05M-$9.84M-$6.80M-$33.63M-$13.52M-$4.63M-$9.27M-$16.18M-$6.51M
    Net income-$11.26M-$4.29M-$22.95M-$10.85M-$9.74M-$6.67M-$33.51M-$13.49M-$4.53M-$9.13M-$15.99M-$6.49M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $428.00K by $11.15M. Shareholder equity was negative, at -$31.46M, as total liabilities of $57.22M exceeded total assets of $25.76M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$25.76M$35.08M$74.89M$100.09M$159.56M$55.42M$39.86M$9.52M$10.22M$14.45M
    Current assets$15.31M$11.76M$10.70M$25.54M$39.14M$9.23M$22.96M$8.64M$8.53M$12.70M
    Cash and equivalents$11.58M$8.64M$9.43M$19.99M$32.95M$7.14M$22.07M$8.03M$7.60M$10.17M
    Total liabilities$57.22M$47.35M$49.30M$60.50M$94.35M$21.94M$9.02M$6.09M$5.81M$4.58M
    Short-term debt$428.00K$228.00K$2.31M$109.00K$1.31M$2.39M$1.13M$800.00K$1.14M$202.00K
    Long-term debtN/AN/AN/AN/AN/A$1.51M$1.91M$347.00K$1.07M$0
    Shareholder equity-$31.46M-$12.27M$20.47M$34.29M$65.22M$33.48M$30.84M$3.42M$4.40M$9.86M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$29.44M$40.43M$25.76M$43.94M$50.52M$60.36M$35.08M$70.22M$74.72M$70.97M$74.89M$81.59M
    Total liabilities$50.74M$51.12M$57.22M$53.13M$49.42M$50.14M$47.35M$60.51M$52.02M$54.05M$49.30M$39.10M
    Cash and equivalents$17.76M$28.20M$11.58M$18.69M$24.29M$31.03M$8.64M$3.36M$9.26M$5.58M$9.43M$13.78M
    Shareholder equity-$21.30M-$10.69M-$31.46M-$9.20M$1.10M$10.22M-$12.27M$9.71M$22.70M$11.59M$20.47M$37.56M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$22.18M-$20.69M-$23.32M-$45.57M-$35.94M-$25.98M-$19.71M-$11.65M-$13.38M-$7.52M
    Capital expenditures$3.19M$516.00K$281.00K$4.34M$2.25M$1.23M$918.00K$31.00K$91.00K$106.00K
    Free cash flow-$25.37M-$21.20M-$23.61M-$49.91M-$38.19M-$27.21M-$20.63M-$11.68M-$13.48M-$7.63M
    Dividends paidN/AN/AN/AN/AN/AN/AN/A$96.00KN/AN/A
    Share repurchases$487.00K$1.37M$427.00K$389.00K$2.67M$58.00K$3.29M$65.00K$0$773.00K
    Investing cash flow-$3.19M-$512.00K-$932.00K-$4.34M-$13.96M-$11.75M-$12.41M-$31.00K$843.00K-$181.00K
    Financing cash flow$28.07M$20.43M$12.19M$35.81M$78.36M$22.80M$47.87M$12.11M$9.97M$9.88M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$9.27M-$7.64M-$5.54M-$4.50M-$6.17M-$5.84M-$5.35M-$5.53M-$5.98M-$3.83M-$4.42M-$3.77M
    Capital expenditures$779.00K$613.00K$1.48M$1.05M$349.00K$307.00K$214.00K$87.00K$191.00K$24.00K$264.00K$17.00K
    Free cash flow-$10.05M-$8.25M-$7.02M-$5.55M-$6.52M-$6.15M-$5.57M-$5.62M-$6.17M-$3.85M-$4.69M-$3.79M
    Last 12 quarters

    Frequently Asked Questions About IMDX

    What is Insight Molecular Diagnostics' annual revenue?

    Insight Molecular Diagnostics reported revenue of $4.05M for the fiscal year ended Dec 31, 2025.

    How fast is Insight Molecular Diagnostics' revenue growing?

    Revenue was up 115.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 61.8%.

    Is Insight Molecular Diagnostics profitable?

    No. Insight Molecular Diagnostics reported net income of -$50.22M for the fiscal year ended Dec 31, 2025, with a net margin of -1238.5%.

    How much free cash flow does IMDX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$22.18M minus capital expenditures of $3.19M produced free cash flow of -$25.37M.

    How much debt does Insight Molecular Diagnostics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $428.00K and cash and equivalents of $11.58M.